### (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

# (19) World Intellectual Property Organization

International Bureau



# 1 | 1680 | 1449 | 15 | 1644 | 1644 | 1644 | 1645 | 17 | 18 | 1644 | 1645 | 1645 | 1645 | 1645 | 1645 | 1645 |

(43) International Publication Date 4 March 2004 (04.03.2004)

(10) International Publication Number WO 2004/018708 A3

(51) International Patent Classification<sup>7</sup>:

C12Q 1/68

SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,

(21) International Application Number:

PCT/EP2003/008298

(22) International Filing Date: 28 July 2003 (28.07.2003)

(25) Filing Language:

English

(26) Publication Language:

**English** 

(30) Priority Data:

02017758.0

9 August 2002 (09.08.2002)

- (71) Applicant (for all designated States except US): BAYER HEALTHCARE AG [DE/DE]; 51368 Leverkusen (DE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): Stephan [DE/DE]; Düsseldorfer Str. 35, 51145 Köln (DE). KALLABIS, Harald [DE/DE]; Wolfskaul 8, 51061 Köln (DE). REIFENBERGER, Elke [DE/DE]; Kölnstr. 67, 53757 Sankt Augustin (DE). STROPP, Udo [DE/DE]; Suitbertusweg 8, 42781 Haan (DE). SCHMITZ, Gerd [DE/DE]; Turmstr. 15a, 93161 Sinzing (DE).
- (74) Agent: BAYER HEALTHCARE AG; Law and Patents, Patents and Licensing, 51368 Leverkusen (DE).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,

UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Declaration under Rule 4.17:

as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

## Published:

with international search report

(88) Date of publication of the international search report: 26 August 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: GENETIC POLYMORPHISMS SENSITIVELY PREDICTING ADVERSE DRUG REACTIONS (ADR) AND DRUG **EFFICACY** 


(57) Abstract: The invention provides diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy or whether the human subject is a high or low responder or a good a or bad metabolizer of statins. The invention provides further diagnostic methods and kits including antibodies determining whether a human subject is at risk for a cardiovascular disease. Still further the invention provides polymorphic sequences and other genes. The present invention further relates to isolated polynucleotides encoding a phenotype associated (PA) gene polypeptide useful in methods to identify therapeutic agents and useful for preparation of a medicament to treat cardiovascular disease or influence drug response, the polynucleotide is selected from the group comprising: SEQ ID 1-21 with allelic variation as indicated in the sequences section contained in a functional surrounding like full length cDNA for PA gene polypeptide and with or without the PA gene promoter sequence.





A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12Q1/68								
According to International Patent Classification (IPC) or to both national classification and IPC								
B. FIELDS SEARCHED								
Minimum documentation searched (classification system followed by classification symbols)								
IPC 7	C12Q							
Documentat	ion searched other than minimum documentation to the extent that s	such documents are included. In the fields coa	rohod					
		real real manager in the holds sea	ioneu					
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)								
EPO-Internal, Sequence Search, WPI Data, PAJ, BIOSIS, EMBASE								
	,,,,,,,	,,						
C. DOCUMI	ENTS CONSIDERED TO BE RELEVANT							
Category °	Citation of document, with indication, where appropriate, of the re-	Relevant to claim No.						
v	110 00 (CACOO A (AVVO DUEN TUE)		1.10					
Х	WO 99/64630 A (AXYS PHARM INC) 16 December 1999 (1999-12-16)		1–16					
	abstract							
	page 16, line 9 - line 10 See SEQ ID NO:1,2							
	3ee 3EQ 1D NO.1,2							
Ì								
1								
Furl	ther documents are listed in the continuation of box C.	Patent family members are listed in	annex.					
° Special co	ategories of cited documents :	"T" later document published after the inte	mational filing date					
"A" document defining the general state of the art which is not clted to understand the principle or theory underlying the								
"E" earlier document but published on or after the international "X" document of particular relevance; the claimed invention								
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another "Y" document of particular relevance; the deligned invention								
"O" docum	citation or other special reason (as specified)  "O" document referring to an oral disclosure, use, exhibition or  "O" document is combined with one or more other such document							
"P" docum	means ant published prior to the international filing date but	ments, such combination being obvious in the art.	is to a person skilled					
later	than the priority date claimed	"&" document member of the same patent	<del></del>					
Date of the actual completion of the international search  Date of mailing of the international search report  2 6. 05, 04								
1	19 January 2004	£ 50, UJ, U4						
Name and mailing address of the ISA Authorized officer								
	European Patent Office, P.B. 5818 Patentiaan 2 NL – 2280 HV Rijswijk Tel (431–70) 340–2040 Tv 31 551 openi							
1	Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Sprinks, M						





Box Ι <sup>7</sup> Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)					
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:					
1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:					
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:					
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).					
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)					
This International Searching Authority found multiple inventions in this international application, as follows:					
see additional sheet					
1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.					
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.					
3. As only some of the required additional search fees were timely paid by the applicant, this international Search Report covers only those claims for which fees were paid, specifically claims Nos.:					
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  1-16 partially					
Remark on Protest  The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.					

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-16 partially

Allelic variants relating to SEQ ID NO:1 and subject-matter associated therewith.

2. claims: 1-16 partially

Inventions 2-21: Allelic variants relating to SEQ ID NO:2-21 respectively and subject-matter associated therewith.

# INTERNATION SEARCH REPORT

International Application No P 03/08298

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9964630	A	16-12-1999	AU EP WO US US	4433299 A 1086243 A1 9964630 A1 2003099977 A1 6448003 B1	30-12-1999 28-03-2001 16-12-1999 29-05-2003 10-09-2002